AbbVie acquires Apogee Therapeutics for $10.9 billion.
AbbVie announced an agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash. The acquisition targets Apogee's pipeline of immunology and inflammatory disease treatments. The deal represents a significant expansion of AbbVie's immunology portfolio.
3
Divergence score
3 outlets covered it, splitting into 3 framing camps across 2 bias groups.
3 camps
2 bias groups
Market signalBETA
The spectrum · how 3 outlets placed this story
LeftCenterRight
Reuters
Wall Street Journal
Financial Times
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
Reuters
AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push
strategic growth focus · positive
Wall Street Journal
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
transaction structure focus · neutral
First to report
- Wall Street Journalfirst
- Financial Times+6 min
- Reuters+36 min
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
All three outlets report identical deal terms. Reuters emphasizes the next-generation immunology growth push, WSJ leads with the $10.9 billion in cash structure, and FT highlights the inflammatory disease drug target.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 3 outlets
“AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push”
“AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash”
“AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug”
3 tracked claims across 3 outlets
Fact ledger
All3Corroborated3
3/3
Corroborated
AbbVie is acquiring Apogee Therapeutics for approximately $10.9 billion.
Corroborated
Disputed
2 more tracked claimsSign up free to see the full ledger